- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01241760
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection
A Randomized, Open-Label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
This is a randomized (study drug assigned by chance), open-label (all persons know the study drug assignment) multicenter study to evaluate the effectiveness of telaprevir administered orally as 1125 milligram (mg) twice daily versus 750mg every 8 hours in combination with Peg-IFN-alfa-2a, administered via intramuscular injection once a week, and ribavirin, administered as an oral tablet twice a day, in treatment-naïve study participants with chronic hepatitis C virus (HCV) genotype 1 infection.
Telaprevir will be given orally (by mouth) from Day 1 through Week 12 as 3 tablets (1125mg) twice daily or 2 tablets (750mg) every 8 hours. Peg-IFN-alfa-2a will be administered once a week as an injection under the skin (180 microgram/week) from Day 1 through Week 24 or 48 (based on the patient's treatment response on week 4). Ribavirin is administered orally (by mouth) twice daily from Day 1 through Week 24 or 48 (based on the participant's treatment response on week 4) as 1,000-1,200 mg per day. After the end of treatment (Week 24, Week 48, or at early discontinuation of all study drugs), participants with undetectable HCV RNA at end of treatment will be required to attend follow-up visits until Week 72 safety/tolerability assessments will be performed throughout the treatment period and during the follow-up period.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
-
Adelaide, Australië
-
Camperdown, Australië
-
Clayton, Australië
-
Darlinghurst, Australië
-
Fitzroy, Australië
-
Greenslopes, Australië
-
Melbourne, Australië
-
Perth, Australië
-
-
-
-
-
Antwerpen, België
-
Brussels, België
-
Genk, België
-
Gent, België
-
Leuven, België
-
Liege, België
-
-
-
-
-
Campinas, Brazilië
-
Salvador, Brazilië
-
Santo Andre, Brazilië
-
Sao Paulo, Brazilië
-
São Paulo, Brazilië
-
-
-
-
-
Berlin, Duitsland
-
Bochum, Duitsland
-
Essen, Duitsland
-
Frankfurt, Duitsland
-
Hamburg, Duitsland
-
Kiel, Duitsland
-
Mainz, Duitsland
-
Regensburg, Duitsland
-
-
-
-
-
Clichy, Frankrijk
-
Creteil, Frankrijk
-
Grenoble, Frankrijk
-
Lille, Frankrijk
-
Lyon, Frankrijk
-
Paris, Frankrijk
-
Pessac, Frankrijk
-
Vandoeuvre Les Nancy, Frankrijk
-
Villejuif Cedex, Frankrijk
-
-
-
-
-
Dublin, Ierland
-
Dublin 9, Ierland
-
-
-
-
-
Mex Ctity, Mexico
-
Mexico, Mexico
-
Monterrey, Mexico
-
-
-
-
-
Graz N/A, Oostenrijk
-
Linz, Oostenrijk
-
Wien, Oostenrijk
-
-
-
-
-
Bialystok, Polen
-
Bydgoszcz, Polen
-
Czeladz, Polen
-
Kielce, Polen
-
Krakow, Polen
-
Warszawa, Polen
-
-
-
-
-
Barcelona, Spanje
-
Barcelona N/A, Spanje
-
Madrid, Spanje
-
Malaga N/A, Spanje
-
Santander N/A, Spanje
-
Sevilla N/A, Spanje
-
Valencia, Spanje
-
-
-
-
-
Birmingham, Verenigd Koninkrijk
-
Edinburgh, Verenigd Koninkrijk
-
Glasgow, Verenigd Koninkrijk
-
London, Verenigd Koninkrijk
-
Manchester, Verenigd Koninkrijk
-
-
-
-
California
-
La Jolla, California, Verenigde Staten
-
Los Angeles, California, Verenigde Staten
-
San Diego, California, Verenigde Staten
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten
-
-
Connecticut
-
New Haven, Connecticut, Verenigde Staten
-
-
Florida
-
Bradenton, Florida, Verenigde Staten
-
Jacksonville, Florida, Verenigde Staten
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten
-
Marietta, Georgia, Verenigde Staten
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten
-
Downers Grove, Illinois, Verenigde Staten
-
-
Louisiana
-
New Orleans, Louisiana, Verenigde Staten
-
-
Maryland
-
Lutherville, Maryland, Verenigde Staten
-
-
Missouri
-
Kansas City, Missouri, Verenigde Staten
-
-
New Hampshire
-
Lebanon, New Hampshire, Verenigde Staten
-
-
New Jersey
-
Egg Harbor Twp, New Jersey, Verenigde Staten
-
-
New Mexico
-
Santa Fe, New Mexico, Verenigde Staten
-
-
New York
-
New York, New York, Verenigde Staten
-
-
North Carolina
-
Charlotte, North Carolina, Verenigde Staten
-
Durham, North Carolina, Verenigde Staten
-
Statesville, North Carolina, Verenigde Staten
-
Winston Salem, North Carolina, Verenigde Staten
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten
-
-
Pennsylvania
-
Allentown, Pennsylvania, Verenigde Staten
-
Hershey, Pennsylvania, Verenigde Staten
-
Philadelphia, Pennsylvania, Verenigde Staten
-
Pittsburgh, Pennsylvania, Verenigde Staten
-
-
Rhode Island
-
Providence, Rhode Island, Verenigde Staten
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten
-
Columbia, South Carolina, Verenigde Staten
-
-
Texas
-
Arlington, Texas, Verenigde Staten
-
Dallas, Texas, Verenigde Staten
-
Houston, Texas, Verenigde Staten
-
San Antonio, Texas, Verenigde Staten
-
-
Virginia
-
Falls Church, Virginia, Verenigde Staten
-
Norfolk, Virginia, Verenigde Staten
-
-
Washington
-
Seattle, Washington, Verenigde Staten
-
-
-
-
-
Göteborg, Zweden
-
Malmö, Zweden
-
Stockholm, Zweden
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patient has chronic HCV infection genotype 1 with HCV RNA level > 1,000 IU/mL
- Patients should not have had any previous treatment for hepatitis C
- Patient must have documentation of a liver biopsy within 2 years before the screening visit or the patient must agree to have a biopsy performed within the screening period
- Patients with cirrhosis should have serum alpha-fetoprotein (AFP) <= 50 ng/mL. If AFP > 50 ng/mL, absence of a mass must be demonstrated by ultrasound within the screening period
- A female patient of childbearing potential and a nonvasectomized male patient who has a female partner of childbearing potential must agree to the use of 2 effective methods of birth control from screening until 6 months (female patient) or 7 months (male patient) after the last dose of RBV.
Exclusion Criteria:
- Patient is infected or co-infected with HCV of another genotype than genotype 1 and/or patient is infected with more than one genotype subtype
- Patient has a pre-existing psychiatric condition
- Patient has history of decompensated liver disease or shows evidence of significant liver disease in addition to hepatitis C
- Patient has human immunodeficiency virus (HIV) or hepatitis B virus (HBV) co-infection
- Patient has active malignant disease or history of malignant disease within the past 5 years (with the exception of treated basal cell carcinoma).
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: 001 T(q8h) / PR
Telaprevir (T) 750 mg (2 oral tablets) every 8 hours for 12 weeks, in combination with pegylated interferon (P) and ribavirin (R)
|
Ribavirin (RBV) 1000-1200 milligram (mg) per day (weight dependent) twice daily regimen oral tablets for 24 or 48 weeks depending on the patient's treatment response at week 4
1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks
180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks Pegylated interferon alfa-2a 180 microgram (µg) per week subcutaneous injection for 24 or 48 weeks depending on the patient's treatment response at week 4
750 mg (2 oral tablets) every 8 hours for 12 weeks
|
Experimenteel: 002 T(b.i.d.) / PR
Telaprevir (T) 1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks, in combination with pegylated interferon (P) and ribavirin (R)
|
Ribavirin (RBV) 1000-1200 milligram (mg) per day (weight dependent) twice daily regimen oral tablets for 24 or 48 weeks depending on the patient's treatment response at week 4
1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks
180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks Pegylated interferon alfa-2a 180 microgram (µg) per week subcutaneous injection for 24 or 48 weeks depending on the patient's treatment response at week 4
750 mg (2 oral tablets) every 8 hours for 12 weeks
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Drugs (SVR12 Planned)
Tijdsspanne: End of trial, 12 weeks after last planned dose
|
The table below shows the percentage of participants achieving Sustained Virologic Response 12 weeks after last planned dose of study medication (SVR12 planned).
SVR was defined as having Hepatitis C Virus (HCV) ribonucleic acid (RNA) levels less than 25 international units/milliliter (IU/mL).
|
End of trial, 12 weeks after last planned dose
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Percentage of Participants With Sustained Virologic Response 24 Weeks After the Last Planned Dose of Study Drugs (SVR24 Planned)
Tijdsspanne: End of trial, 24 weeks after last planned dose
|
The table below shows the percentage of participants achieving SVR 24 weeks after the last planned dose of study medication.
SVR was defined as having Hepatitis C Virus (HCV) ribonucleic acid (RNA) levels less than 25 international units/milliliter (IU/mL).
The response for T12(b.i.d)/PR group is higher than that after 12 weeks because HCV RNA data for two participants were missing for SVR assessment at that time.
Consequently, by definition of SVR12, they were counted as not having achieved SVR12.
|
End of trial, 24 weeks after last planned dose
|
Percentage of Participants With Sustained Virologic Response 72 Weeks After the Start of Study Medication (SVR72 Planned)
Tijdsspanne: End of trial, 72 weeks after the start of study medication
|
The table below shows the percentage of participants achieving SVR 72 weeks after the start of study medication (SVR72 planned).
SVR was defined as having plasma Hepatitis C Virus (HCV) ribonucleic acid (RNA) levels less than 25 IU/mL, target not detected, at end of treatment and up to 72 weeks after start of study medication (i.e., no confirmed detectable HCV RNA in between).
|
End of trial, 72 weeks after the start of study medication
|
Percentage of Participants Achieving Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values of Less Than 25 IU/ml, Target Not Detected, at Different Time Points.
Tijdsspanne: Baseline, Week 4 and Week 4+12.
|
The table below shows the percentage of participants with undetectable hepatitis C virus (HCV) ribonucleic acid (RNA) levels, which means less than 25 IU/ml, target not detected, at different time points during the study.
|
Baseline, Week 4 and Week 4+12.
|
Percentage of Participants With On-treatment Virologic Failure Which Required Them to Permanently Discontinue All Study Drugs
Tijdsspanne: Week 4, 12, 24, 32, 40
|
The table below shows the percentage of participants who met a stopping rule, defined as having a hepatitis C virus (HCV) ribonucleic acid (RNA) value at Week 4 >1000 IU/mL and at Weeks 12, 24, 32 and 40 ≥25 IU/mL.
|
Week 4, 12, 24, 32, 40
|
Percentage of Participants Who Relapsed During Follow-up Period
Tijdsspanne: During Follow-Up (24 weeks after the last dose of study drug)
|
The table below shows the percentage of participants who relapsed (ie, those having confirmed detectable hepatitis C virus [HCV] ribonucleic acid [RNA] during the 12-week follow-up period after previous HCV RNA <25 IU/mL, target not detected, at end of treatment).
|
During Follow-Up (24 weeks after the last dose of study drug)
|
Percentage of Participants of Each IL28B Genotype Achieving Sustained Virologic Response 12 Weeks After the Last Planned Dose of Study Medication (SVR12 Planned)
Tijdsspanne: End of trial, 12 weeks after the last planned dose
|
The table below shows the effect of interleukin 28B (IL28B) gene's subtype (CC, CT or TT genotype) on the primary outcome measure: SVR12 planned.
|
End of trial, 12 weeks after the last planned dose
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Publicaties en nuttige links
Algemene publicaties
- Sarrazin C, Dierynck I, Cloherty G, Ghys A, Janssen K, Luo D, Witek J, Buti M, Picchio G, De Meyer S. An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay. J Clin Microbiol. 2015 Apr;53(4):1264-9. doi: 10.1128/JCM.03030-14. Epub 2015 Feb 4.
- Buti M, Agarwal K, Horsmans Y, Sievert W, Janczewska E, Zeuzem S, Nyberg L, Brown RS Jr, Hezode C, Rizzetto M, Parana R, De Meyer S, De Masi R, Luo D, Bertelsen K, Witek J. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C. Gastroenterology. 2014 Mar;146(3):744-753.e3. doi: 10.1053/j.gastro.2013.11.047. Epub 2013 Dec 4.
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Ziekten van het spijsverteringsstelsel
- RNA-virusinfecties
- Infecties
- Door bloed overgedragen infecties
- Overdraagbare ziekten
- Lever Ziekten
- Flaviviridae-infecties
- Hepatitis, viraal, menselijk
- Enterovirusinfecties
- Picornaviridae-infecties
- Hepatitis
- Hepatitis A
- Hepatitis C
- Virusziekten
- Hepatitis, chronisch
- Hepatitis C, chronisch
- Fysiologische effecten van medicijnen
- Moleculaire mechanismen van farmacologische werking
- Anti-infectieuze middelen
- Antivirale middelen
- Antimetabolieten
- Antineoplastische middelen
- Immunologische factoren
- Interferonen
- Interferon-alfa
- Ribavirine
- Peginterferon alfa-2a
- Interferon alfa-2
Andere studie-ID-nummers
- CR013711
- OPTIMIZE-HCV (Andere identificatie: Janssen Infectious Diseases BVBA)
- VX-950-C211 (Andere identificatie: Janssen Infectious Diseases BVBA)
- 2010-021628-84 (EudraCT-nummer)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Genotype 1 chronische hepatitis C
-
Trek Therapeutics, PBCVoltooidChronische Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C virale infectieVerenigde Staten, Nieuw-Zeeland
-
AbbVie (prior sponsor, Abbott)VoltooidChronische Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV)Verenigde Staten, Australië, Canada, Frankrijk, Duitsland, Nieuw-Zeeland, Puerto Rico, Spanje, Verenigd Koninkrijk
-
AbbVie (prior sponsor, Abbott)VoltooidHepatitis C | Chronische hepatitis C-infectie | HCV | Hepatitis C Genotype 1Verenigde Staten
-
AbbVie (prior sponsor, Abbott)VoltooidHepatitis C | Chronische hepatitis C-infectie | HCV | Hepatitis C Genotype 1Verenigde Staten, Puerto Rico
-
University College London HospitalsVoltooidChronische Hepatitis C, HCV Genotype 1Verenigd Koninkrijk
-
Göteborg UniversityKarolinska University Hospital; Sahlgrenska University Hospital, Sweden; Skane... en andere medewerkersVoltooidChronische hepatitis C, genotype 1Zweden
-
Merck Sharp & Dohme LLCVoltooidChronische Hepatitis C Genotype 1
-
Janssen-Cilag International NVVoltooidGenotype 1 chronische hepatitis CRussische Federatie
-
HanAll BioPharma Co., Ltd.VoltooidChronische hepatitis C-infectie | Genotype 1Verenigde Staten
-
GlobeImmuneVoltooid
Klinische onderzoeken op Ribavirin
-
Children's Hospital of Fudan UniversityWeihai Rensheng PharmacyVoltooid
-
Prof. Facchinetti FabioMerck Sharp & Dohme LLCVoltooid
-
University of Colorado, DenverJanssen Scientific Affairs, LLCBeëindigdHepatitis CVerenigde Staten
-
Azienda Ospedaliera San Camillo ForlaniniVoltooid
-
Baqiyatallah Medical Sciences UniversityShahid Beheshti University of Medical Sciences; Guilan University of Medical... en andere medewerkersVoltooidHemofilie | Hepatitis CIran, Islamitische Republiek
-
Baqiyatallah Medical Sciences UniversityGuilan University of Medical Sciences; Baqiyatallah Research Center for Gastroenterology... en andere medewerkersVoltooidHepatitis C | ThalassemieIran, Islamitische Republiek
-
Mashhad University of Medical SciencesVoltooidChronische Hepatitis CIran, Islamitische Republiek
-
Xi'an International Medical Center HospitalVoltooid